Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 11 - 20 of about 78   

Articles published

CBST 68.11 -0.42 (-0.61%)
price chart
Cubist Pharmaceuticals Receives Average Rating of �Buy� from Brokerages ...
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has been given an average rating of �Buy� by the fourteen brokerages that are currently covering the company, Stock Ratings Network.com reports. Four research analysts have rated the ...
Related articles »  
Investors Are Watching: Cubist Pharmaceuticals (NASDAQ:CBST), Medivation ...
TheStreet Quant Ratings rates Cubist Pharmaceuticals Inc. (NASDAQ:CBST) as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share and expanding profit margins.
News Buzz : Cubist Pharmaceuticals Inc. (NASDAQ:CBST), China Yuchai ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) announced, it is recalling 101 production lots of its antibiotic Cubicin (daptomycin injection) amid fear of glass particles being present in the drug.
Related articles »  
Insider Selling: Steven C. Gilman Sells 40625 Shares of Cubist Pharmaceuticals ...
Cubist Pharmaceuticals (NASDAQ:CBST) traded up 0.24% during mid-day trading on Tuesday, hitting $61.55. 1,050,994 shares of the company's stock traded hands. Cubist Pharmaceuticals has a one year low of $55.71 and a one year high of $82.12.
Hot Stocks : Plug Power Inc. (NASDAQ:PLUG), Cubist Pharmaceuticals Inc ...
Plug Power Inc. (NASDAQ:PLUG)'s shares declined 2.60% to $5.62. The company on July 29 confirms the company has received a follow-on GenKey purchase order from Wal-Mart Stores, Inc. to add an additional, seventh, GenKey site to the original six-site ...
Trending Tickers: Cubist Pharmaceuticals (NASDAQ:CBST), Cempra (NASDAQ ...
Cubist Pharmaceuticals Inc (CBST) announced yesterday, it is recalling 101 production lots of its antibiotic Cubicin (daptomycin injection) amid fear of glass particles being present in the drug.
Related articles »  
Cubist Pharmaceuticals Given Consensus Recommendation of "Buy" by ...
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has been given a consensus recommendation of �Buy� by the fourteen analysts that are currently covering the company, American Banking & Market News reports. Four investment ...
Cubist Pharmaceuticals Given Consensus Rating of �Buy� by Brokerages ...
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) has been given a consensus rating of �Buy� by the fifteen ratings firms that are covering the company, AnalystRatings.Net reports. Five research analysts have rated the stock with a hold ...
Watch List: IXYS Corp. (NASDAQ:IXYS), Cubist Pharmaceuticals (NASDAQ ...
Cubist Pharmaceuticals Inc. (NASDAQ:CBST) has announced it is voluntarily recalling nine lots of CUBICIN (daptomycin for injection) to the user level following complaints of foreign particulate matter in reconstituted vials.
Cubist to Present at Morgan Stanley Global Healthcare Conference
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment.
Related articles »